Dapagliflozin, a potent and selective SGLT2 inhibitor, has been shown to improve glycemic control in patients with type 2 diabetes when used as monotherapy [8] or in combination with metformin [9], sulfonylureas [10,11], thiazolidinedione [12], or insulin [6,13]. This evidence concerns the gene INS and type 2 diabetes mellitus.